Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...120121122123124125126127128129130...401402»
  • ||||||||||  Journal:  A nomogram to predict the risk of sarcopenia in older people. (Pubmed Central) -  Apr 25, 2023   
    The Hosmer-Lemeshow test had a P value of .94. The predictive model in this study will be a clinically useful tool for predicting the risk of sarcopenia, and it will facilitate earlier detection and therapeutic intervention for sarcopenia.
  • ||||||||||  Journal:  Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy: Sarcopenia Adds Insult to Injury. (Pubmed Central) -  Apr 25, 2023   
    Sarcopenia is present in nearly half of the cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt, which increases the risk of a single episode of hepatic encephalopathy by 3-fold and that of multiple episodes of hepatic encephalopathy by 8-fold after transjugular intrahepatic portosystemic shunt procedure. Increased skeletal muscle index is associated with decreased risk of hepatic encephalopathy.
  • ||||||||||  Journal:  Bioimpedance phase angle is independently associated with myosteatosis: The Shizuoka study. (Pubmed Central) -  Apr 24, 2023   
    Improvement and maintenance of perioperative muscle mass are important to maintain good nutritional parameters. Leg PhA was independently associated with mean attenuated value of the mid-thigh skeletal muscle, suggesting that the assessment of PhA in combination with SMI could provide additional information for the evaluation of muscle properties.
  • ||||||||||  Genetic Medicine Using a PLV Approach Reduces Frailty and Improves Healthspan (Board No. 1008) -  Apr 21, 2023 - Abstract #ASGCT2023ASGCT_1703;    
    Our data shows that senolytic FAST-PLVs improved healthspan and reduced frailty in naturally aged mice.We separately measured the effect on muscle growth by a FAST-PLV Follistatin therapy. Up to 9 months after one treatment, muscle weight and fiber size were significantly increased resulting in increased body weight and functional grip strength.In summary, our approaches represent a first-in-class therapeutic that targets cells based on transcriptional activity, rather than surface markers or metabolism, and represents a viable strategy for treating age-related diseases such as physical frailty and sarcopenia.
  • ||||||||||  Observational data, Journal:  Letter to the (Pubmed Central) -  Apr 21, 2023   
    Body compositions could not only be noninvasively used for nutritional assessment, but also be utilized to predict HE risk of cirrhotic patients after TIPS. No abstract available
  • ||||||||||  Journal:  Sarcopenia???low muscle mass. (Pubmed Central) -  Apr 20, 2023   
    Interdisciplinary team assessment would be beneficial to enhance the quality of life and attenuate the development of comorbidities in subjects with ABI. No abstract available
  • ||||||||||  Journal:  Sarcopenia in chronic kidney disease: from bench to bedside. (Pubmed Central) -  Apr 20, 2023   
    A variety of potential therapeutic drugs targeting these muscle-wasting mechanisms in CKD have been investigated, but most of the trials focused on aged patients without CKD, and none of these drugs have been approved for the treatment of sarcopenia so far. Further studies on the molecular mechanisms of sarcopenia in CKD and targets for potential therapeutics are needed to improve the outcomes of sarcopenic patients with CKD.
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Protein Quality to Support Increased Muscle Protein Synthesis (clinicaltrials.gov) -  Apr 20, 2023   
    P=N/A,  N=45, Completed, 
    Further studies on the molecular mechanisms of sarcopenia in CKD and targets for potential therapeutics are needed to improve the outcomes of sarcopenic patients with CKD. Recruiting --> Completed | Trial completion date: May 2024 --> Jan 2023 | Trial primary completion date: Dec 2023 --> Jan 2023
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Glucose Metabolism, Muscle Mass/Function and Inflammation in the Elderly (clinicaltrials.gov) -  Apr 19, 2023   
    P=N/A,  N=76, Completed, 
    Recruiting --> Completed | Trial completion date: May 2024 --> Jan 2023 | Trial primary completion date: Dec 2023 --> Jan 2023 Unknown status --> Completed
  • ||||||||||  pemetrexed / Generic mfg.
    Biomarker, Retrospective data, Journal:  Predictive factors associated with pemetrexed acute toxicity. (Pubmed Central) -  Apr 19, 2023   
    To conclude, ELT induced by pemetrexed-based treatments occur frequently in cancer patients in a real-world setting. A pretherapeutic assessment before pemetrexed initiation should include three major checkpoints: use of proton pump inhibitors, sarcopenia, and denutrition evaluation.
  • ||||||||||  Enrollment closed, Trial primary completion date:  KEHS: The Kunshan Elderly Health Study (clinicaltrials.gov) -  Apr 18, 2023   
    P=N/A,  N=5945, Active, not recruiting, 
    PNI can help clinicians guide multimodal interventions to preserve muscle and optimize survival outcomes. Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2022 --> Dec 2032